Detail Data
Volume (24h): 624,025 shares
P/E Ratio: /
Forward P/E: -2.62
EPS: -13.95
Forward EPS: -11.11
Number of Shares: 0 shares
Market Capitalization: /

Dividend

Dividend Value
Dividend Amount According to our data, the company Mersana Therapeutics does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a hold recommendation for Mersana Therapeutics stock. The current number of analysts covering this company is 1. The highest target price is 30.75 , while the lowest target price is 30.75 . The median target valuation set by analysts is 30.75 . These forecasts and recommendations provide insight into how analysts view the future stock performance of Mersana Therapeutics.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Mersana Therapeutics stock is: hold
Number of Analysts: 1
Highest Target Price: 30.75
Lowest Target Price: 30.75
Median Target Price: 30.75

Fundamental Indicators

Indicator Data
Total Revenue: 33,180,000.00
Net Income: -70,081,000.00
Price-to-Book (P/B): /
PEG Ratio: /
Exchange:
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 102
Country: United States

Where to Buy Mersana Therapeutics Stock?

You can purchase Mersana Therapeutics stock on the under the ticker symbol: MRSN. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 52%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Mersana Therapeutics Stock

Indicator Value
Company Revenue: 33,180,000.00
EBITDA: -66,290,000.00 - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -13.95
Book Value Per Share: -11.91
Total Cash: 56,391,000.00
Total Cash per Share: 11.28
Total Debt: 2,293,000.00
Debt to Equity Ratio: -
Quick Ratio 1.31
Current Ratio 1.39
Free Cash Flow -43,801,248.00
Operating Cash Flow -74,371,000.00
Gross Margins -108.04 %
EBITDA Margins -199.79 %
Operating Margins -67.91 %
Profit Margins -211.22 %
Return on Assets -36.3 %
Return on Equity -
Earnings Growth (1 year) -
Revenue Growth (1 year) -12.6 %
Quarterly Earnings Year-over-Year Growth -
Market Capitalization -
Enterprise Value 91,265,648.00
EV/Revenue 2.751
EV/EBITDA -1.377
Float Shares 3,530,617 shares
Shares Outstanding 4,998,750 shares
Held Percent Insiders 0.01 %
Held Percent Institutions 67.57 %
Shares Short 54,446
Shares Short Prior Month 300,400
Date Short Interest 2025-12-15
Short Percentage of Total Shares 1.09 %
Short Ratio 0.79
Beta 0.43
Short Percentage of Float 1.19 %
Implied Shares Outstanding 4,998,750

Frequently Asked Questions (FAQ)

According to our data, the company Mersana Therapeutics does not pay dividends yet, even in 2025.

Mersana Therapeutics shares are traded on the stock exchange under the ticker: MRSN. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Mersana Therapeutics shares is from a total of 1 analysts. The average target price prediction is 30.75 per share.

The total number of Mersana Therapeutics shares on the exchange is 4,998,750.00 shares, which at the current market capitalization gives the company a total valuation of 0.00 .